Paul V. Viscuse

Apr 22, 2024 | onclive.com | Paul V. Viscuse

April 22, 2024Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma. The 2024 ASCO Genitourinary Cancers Symposium (ASCO GU 2024), held January 25 to 27, wrapped up in San Francisco with many informative presentations and discussions. One of the major themes from the meeting was the role of adjuvant immunotherapy.

Apr 12, 2024 | jnm.snmjournals.org | Paul V. Viscuse |Michael Devitt |Robert Dreicer |Molecular Imaging

PSMA RADIOPHARMACEUTICAL THERAPYPSMA, also known as glutamate carboxypeptidase II and folate hydrolase 1 and encoded by the FOLH1 gene, is a transmembrane glycoprotein enzyme expressed at the cell surface of more than 90% of prostate cancers at a level up to 100- to 1,000-fold higher than in nonprostate tissues (41). Despite AR regulation of PSMA, expression has also been noted in a subset of AR-negative mCRPC (42).